Clinical trials
Limited Stage Small Cell Lung Cancer clinical trials
Below are recruiting limited stage small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 460 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06295926RecruitingPhase 2
Testing a new immunotherapy with chemo-radiation for limited-stage small cell lung cancer
This trial is testing whether adding the immunotherapy drug serplulimab to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer. It is for those who have not had any previous treatment for their cancer.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06514118Recruiting
Immunotherapy with radiation for advanced small-cell lung cancer
This trial tests a combination of chemotherapy, immunotherapy, and targeted radiation for people with extensive-stage small-cell lung cancer. The goal is to see if adding radiation to leftover tumors after initial treatment helps control the disease better.
Qingdao, ShandongAges 18–80 - NCT06517953RecruitingPhase 2
Testing two targeted pills for rare EGFR lung cancer
This study tests two oral targeted drugs, Befotertinib and Icotinib, in people with advanced lung cancer (NSCLC) that has one of three uncommon EGFR mutations. The trial aims to see how well these pills work when used as the first treatment for your cancer.
Guangzhou, GuangdongAges 18 years+ - NCT06528847RecruitingPhase 2
Adjuvant Benmelstobart for stage IB, grade 3 lung adenocarcinoma
This trial tests whether giving the immunotherapy drug Benmelstobart after surgery can help prevent return of a specific type of lung cancer. It is for people with stage IB, grade 3 (poorly differentiated) lung adenocarcinoma that has been completely removed.
Shanghai, Shanghai MunicipalityAges 18–74 - NCT06534489Recruiting
Surgery for lung cancer after chemo or targeted therapy
This trial tests whether combining chemo or targeted therapy before surgery can help people with non-small cell lung cancer that may require removing a whole lung. We want to see if this approach makes the surgery safer and more effective.
ShanghaiAges 18–75 - NCT07783477RecruitingPhase 1
Armored CAR T cells for DLL3 positive cancers
This trial tests an experimental treatment using your own immune cells, modified to better find and attack cancer cells that carry a marker called DLL3. It is for people with certain neuroendocrine tumors, including small cell lung cancer, who have already tried standard treatments.
Basking Ridge, New JerseyAges 18 years+ - NCT05654454RecruitingPhase 3
Bevacizumab plus chemotherapy vs Avastin for advanced lung cancer
This trial compares a combination of anti-angiogenics (bevacizumab) plus chemotherapy (paclitaxel and carboplatin) against Avastin-based treatment in people with advanced non-small cell lung cancer. It aims to find out whether the study treatment is safer and works better for shrinking tumors and improving outcomes.
ArkhangelskAges 18 years+ - NCT06562920RecruitingPhase 2
Immunotherapy plus chemo and SBRT before surgery for limited-stage small cell lung cancer
This trial tests a combination of immunotherapy (adebrelimab), chemotherapy, and targeted radiation (SBRT) before surgery for people with limited-stage small cell lung cancer. The goal is to see if this approach can shrink tumors and improve outcomes before the main treatment.
Hangzhou, ZhejiangAges 18–75 - NCT07770100RecruitingPhase 2
Matching immunotherapy and targeted radiation for advanced cancer
This trial tests combining immunotherapy (a treatment that boosts your immune system to fight cancer) with a targeted type of radiation called SBRT, which precisely delivers high-dose radiation to multiple cancer spots. The main goal is to see if this combination helps control metastatic cancer (cancer that has spread) better than standard care.
Lexington, KentuckyAges 18–99 - NCT06523673RecruitingPhase 3
SBRT for lung cancer with limited new growth
This trial tests whether a precise type of radiation called SBRT can control lung cancer that has started to grow in only a few new spots while you are on standard treatments. It may help you delay changing to a different treatment.
Hangzhou, ZhejiangAges 18 years+ - NCT07759856RecruitingPhase 2
Natural killer cells plus immunotherapy for small cell lung cancer
This trial tests combining natural killer (NK) cells with an immunotherapy drug as a maintenance treatment after standard chemotherapy for small cell lung cancer that has spread. The goal is to see if this combination can help keep the cancer from growing.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT06141226RecruitingPhase 2
New drug combo for immunotherapy-resistant lung cancer
This trial tests a combination of an immunotherapy drug (TQB2450), a targeted therapy (anlotinib), and chemotherapy for people with advanced non-small cell lung cancer whose cancer stopped responding to prior immunotherapy. It aims to find a new option when the first treatment didn't work anymore.
Huizhou, GuangdongAges 18–75 - NCT07754812RecruitingPhase 4
Oral paclitaxel with immunotherapy and SBRT before surgery for older adults with lung cancer
This trial tests a new way to treat non-small cell lung cancer in people aged 70 or older. You will receive oral chemotherapy (paclitaxel) with immunotherapy and focused radiation (SBRT) before surgery, hoping to shrink the tumor and improve outcomes.
Guangzhou, GuangdongAges 70 years+ - NCT06527898RecruitingPhase 1/Phase 2
Short-course radiation plus immunotherapy for limited-stage small-cell lung cancer
This study tests using a shorter course of radiation (hypofractionated radiotherapy) combined with immunotherapy for people with limited-stage small-cell lung cancer. The goal is to see if this approach works better at controlling the cancer and may cause fewer side effects.
Hefei, AnhuiAges 18–70 - NCT07744698RecruitingPhase 4
Maintenance therapy for advanced lung cancer
This trial tests a pill form of chemotherapy (oral paclitaxel) combined with an immunotherapy drug to keep advanced lung cancer from growing after initial treatment. It may help patients whose cancer was controlled with first-line therapy.
Hefei, AnhuiAges 18–75 - NCT06247163Recruiting
PET-guided radiation for small cell lung cancer
This trial uses PET scans to guide radiotherapy for people with limited-stage small cell lung cancer, aiming to improve treatment accuracy. It is designed for those whose cancer has not spread extensively.
EssenAges 18 years+ - NCT07738172RecruitingPhase 3
Osimertinib with or without lung tumor surgery for EGFR-mutated non-small cell lung cancer
This study tests whether adding surgery to remove the main lung tumor improves outcomes for people with stage 4 lung cancer that has a specific EGFR mutation and only limited spread. If you qualify, you will take the targeted drug osimertinib for 12 weeks, and if the tumor responds, you may be randomly assigned to either continue the drug alone or have the main tumor surgically removed and then continue the drug.
Taipei, Taipei CityAges 18 years+ - NCT05501665RecruitingPhase 1/Phase 2
Adaptive radiation plus pembrolizumab for stage IV lung cancer
This trial tests a personalized (“adaptive”) radiation plan combined with pembrolizumab, and possibly chemotherapy, for advanced stage IV lung cancer. It aims to improve cancer control while carefully managing side effects, including in patients with certain brain metastases.
Nashville, TennesseeAges 18 years+ - NCT07704658RecruitingPhase 4
Pralsetinib drug interaction study for advanced solid tumors
This trial tests how pralsetinib interacts with other drugs in people with advanced solid tumors that have a specific RET gene change. It aims to find the right dose and safety profile.
Logroño, La RiojaAges 18 years+ - NCT04335292RecruitingPhase 2
Osimertinib then chemotherapy for EGFR-mutated lung cancer
This Phase 2 study tests a treatment sequence starting with osimertinib, then using chemotherapy after it. It is meant for people with EGFR-mutated advanced lung cancer whose disease has come back or progressed, including a “rechallenge” attempt with osimertinib.
Vancouver, British ColumbiaAges 18 years+ - NCT05468242RecruitingPhase 2
Tislelizumab after lung cancer chemotherapy and radiation
This Phase 2 study tests tislelizumab (an immune medicine) given after chemotherapy and radiation for stage III non-small cell lung cancer that has not been treated before. It may help improve how well the cancer responds and how long patients can stay in remission, with or without an added medication called bevacizumab.
GuangzhouAges 18–75 - NCT06667154RecruitingPhase 2
Low-dose nivolumab plus chemo for early lung cancer
This trial tests a lower dose of the immunotherapy drug nivolumab (Opdivo) combined with standard chemotherapy before surgery for patients with early-stage non-small cell lung cancer (NSCLC). The goal is to see if this combination shrinks the tumor and improves outcomes with fewer side effects.
São José do Rio Preto, São PauloAges 18 years+ - NCT07669779RecruitingPhase 2
Study of AK146D1 and AK112 for advanced lung cancer
This trial tests a combination of two experimental drugs, AK146D1 and AK112, for people with advanced non-small cell lung cancer that cannot be removed by surgery or treated with standard chemo-radiation. It aims to find out if this combination can shrink tumors or slow cancer growth.
Guangzhou, GuangdongAges 18–75 - NCT06388031RecruitingPhase 2
Re-trying immunotherapy for advanced lung cancer after long-term success
This trial tests whether giving immunotherapy again can help people with advanced non-small cell lung cancer whose disease stayed stable for at least 2 years on their first immunotherapy but then started growing. It aims to see if a second course of treatment can work again.
BeijingAges 18–80
Hear when a new Limited Stage Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for limited stage small cell lung cancer?
- Yes. Clin2 currently lists 460 recruiting limited stage small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a limited stage small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a limited stage small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Limited-stage Small Cell Lung Cancer (LS-SCLC)
- Small Cell Lung Cancer Extensive Stage
- Non-small Cell Lung Cancer Stage III
- Non Small Cell Lung Cancer
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
- Stage IIIA Non-small Cell Lung Cancer
- Lung Cancer Non-Small Cell Cancer (NSCLC)
- Squamous Cell Non-small Cell Lung Cancer
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.